[8-K] Phio Pharmaceuticals Corp. Reports Material Event
Phio Pharmaceuticals (PHIO) filed a Form 8-K dated 25 July 2025 to report two press releases. First, the company executed a comprehensive drug-substance development services agreement with a U.S. manufacturer, securing production for future clinical material. Second, it disclosed that pathology results are now available for four of five patients in the fourth cohort of its ongoing Phase 1b dose-escalation study (NCT 06014086) assessing neoadjuvant INTASYL PH-762. No quantitative safety, efficacy or financial terms were provided; investors must consult Exhibits 99.1 and 99.2 for full details.
Phio Pharmaceuticals (PHIO) ha presentato un modulo 8-K datato 25 luglio 2025 per comunicare due comunicati stampa. In primo luogo, la societ脿 ha stipulato un accordo completo per lo sviluppo di sostanze farmaceutiche con un produttore statunitense, assicurando la produzione del materiale clinico futuro. In secondo luogo, ha reso noto che i risultati patologici sono ora disponibili per quattro dei cinque pazienti nel quarto gruppo del suo studio di fase 1b in corso con aumento di dose (NCT 06014086) che valuta il neoadiuvante INTASYL PH-762. Non sono stati forniti dati quantitativi su sicurezza, efficacia o termini finanziari; gli investitori devono consultare gli Allegati 99.1 e 99.2 per i dettagli completi.
Phio Pharmaceuticals (PHIO) present贸 un Formulario 8-K fechado el 25 de julio de 2025 para informar sobre dos comunicados de prensa. Primero, la compa帽铆a firm贸 un acuerdo integral de servicios para el desarrollo de sustancias farmac茅uticas con un fabricante estadounidense, asegurando la producci贸n de material cl铆nico futuro. Segundo, inform贸 que los resultados patol贸gicos ya est谩n disponibles para cuatro de los cinco pacientes en la cuarta cohorte de su estudio en curso de fase 1b con escalada de dosis (NCT 06014086) que eval煤a el neoadyuvante INTASYL PH-762. No se proporcionaron t茅rminos cuantitativos de seguridad, eficacia o financieros; los inversionistas deben consultar los Anexos 99.1 y 99.2 para m谩s detalles.
Phio Pharmaceuticals (PHIO)電� 2025雲� 7鞗� 25鞚检瀽 8-K 鞏戩嫕鞚� 鞝滌稖頃橃棳 霊� 瓯挫潣 氤措弰鞛愲毳� 氤搓碃頄堨姷雼堧嫟. 觳Ц, 須岇偓電� 氙戈淡 鞝滌“鞐呾泊鞕� 韽磩鞝侅澑 鞎诫 氍检 臧滊皽 靹滊箘鞀� 瓿勳暯鞚� 觳搓舶頃橃棳 頄ロ泟 鞛勳儊 氍检 靸濎偘鞚� 頇曤炒頄堨姷雼堧嫟. 霊橃Ц, 歆勴枆 欷戩澑 1b靸� 鞖╇焿 歃濍焿 鞐瓣惮(NCT 06014086)鞐愳劀 雱� 氩堨Ц 旖旐樃韸胳潣 雼れ劘 氇� 頇橃瀽 欷� 雱� 氇呾棎 雽�頃� 氤戨Μ 瓴瓣臣臧� 鞚挫牅 鞝滉车 臧�電�頃橂嫟瓿� 氚濏様鞀惦媹雼�. 鞎堨爠靹�, 須姤 霕愲姅 鞛 甏�霠� 鞝曤焿鞝� 臁瓣贝鞚� 鞝滉车霅橃 鞎婌晿鞙茧┌, 韴瀽鞛愲摛鞚� 鞝勳泊 靹鸽秬靷暛鞚� 鞙勴暣 攵�搿� 99.1 氚� 99.2毳� 彀胳“頃挫暭 頃╇媹雼�.
Phio Pharmaceuticals (PHIO) a d茅pos茅 un formulaire 8-K dat茅 du 25 juillet 2025 pour annoncer deux communiqu茅s de presse. Premi猫rement, la soci茅t茅 a conclu un accord complet de services de d茅veloppement de substances m茅dicamenteuses avec un fabricant am茅ricain, garantissant la production de mat茅riel clinique futur. Deuxi猫mement, elle a r茅v茅l茅 que les r茅sultats pathologiques sont d茅sormais disponibles pour quatre des cinq patients de la quatri猫me cohorte de son 茅tude de phase 1b en cours avec escalade de dose (NCT 06014086) 茅valuant l鈥橧NTASYL PH-762 en n茅oadjuvant. Aucun d茅tail quantitatif sur la s茅curit茅, l鈥檈fficacit茅 ou les aspects financiers n鈥檃 茅t茅 fourni ; les investisseurs doivent consulter les annexes 99.1 et 99.2 pour plus d鈥檌nformations.
Phio Pharmaceuticals (PHIO) reichte am 25. Juli 2025 ein Formular 8-K ein, um zwei Pressemitteilungen zu melden. Erstens schloss das Unternehmen eine umfassende Vereinbarung 眉ber die Entwicklung von Arzneistoffen mit einem US-amerikanischen Hersteller ab und sicherte so die Produktion von zuk眉nftigen klinischen Materialien. Zweitens gab es bekannt, dass Pathologieergebnisse nun f眉r vier von f眉nf Patienten in der vierten Kohorte seiner laufenden Phase-1b-Dosissteigerungsstudie (NCT 06014086) zur Bewertung des neoadjuvanten INTASYL PH-762 vorliegen. Quantitative Angaben zu Sicherheit, Wirksamkeit oder finanziellen Bedingungen wurden nicht gemacht; Investoren sollten die Anh盲nge 99.1 und 99.2 f眉r vollst盲ndige Details konsultieren.
- Secures U.S. manufacturing partner via a drug-substance development services agreement, strengthening supply-chain readiness.
- Phase 1b PH-762 trial advancing with pathology data now collected for the majority of fourth-cohort patients.
- None.
Insights
TL;DR 鈥� Deal secures supply, trial advances; limited data, modest near-term impact.
The manufacturing services agreement reduces future CMC risk by lining up a domestic source of drug substance, a critical step as PH-762 progresses. Cohort-4 pathology read-outs confirm the Phase 1b study is moving forward, but without safety or efficacy metrics investors cannot assess therapeutic potential. Overall disclosure is constructive yet too thin to materially change valuation until data and economics are released.
TL;DR 鈥� Trial milestone noted, but no outcome metrics.
Reporting pathology availability for 4/5 patients signals the fourth dose level has completed surgery and sample analysis. However, the 8-K omits response, toxicity or pharmacodynamic results, limiting insight into benefit鈥搑isk. The filing is therefore informational rather than value-inflecting.
Phio Pharmaceuticals (PHIO) ha presentato un modulo 8-K datato 25 luglio 2025 per comunicare due comunicati stampa. In primo luogo, la societ脿 ha stipulato un accordo completo per lo sviluppo di sostanze farmaceutiche con un produttore statunitense, assicurando la produzione del materiale clinico futuro. In secondo luogo, ha reso noto che i risultati patologici sono ora disponibili per quattro dei cinque pazienti nel quarto gruppo del suo studio di fase 1b in corso con aumento di dose (NCT 06014086) che valuta il neoadiuvante INTASYL PH-762. Non sono stati forniti dati quantitativi su sicurezza, efficacia o termini finanziari; gli investitori devono consultare gli Allegati 99.1 e 99.2 per i dettagli completi.
Phio Pharmaceuticals (PHIO) present贸 un Formulario 8-K fechado el 25 de julio de 2025 para informar sobre dos comunicados de prensa. Primero, la compa帽铆a firm贸 un acuerdo integral de servicios para el desarrollo de sustancias farmac茅uticas con un fabricante estadounidense, asegurando la producci贸n de material cl铆nico futuro. Segundo, inform贸 que los resultados patol贸gicos ya est谩n disponibles para cuatro de los cinco pacientes en la cuarta cohorte de su estudio en curso de fase 1b con escalada de dosis (NCT 06014086) que eval煤a el neoadyuvante INTASYL PH-762. No se proporcionaron t茅rminos cuantitativos de seguridad, eficacia o financieros; los inversionistas deben consultar los Anexos 99.1 y 99.2 para m谩s detalles.
Phio Pharmaceuticals (PHIO)電� 2025雲� 7鞗� 25鞚检瀽 8-K 鞏戩嫕鞚� 鞝滌稖頃橃棳 霊� 瓯挫潣 氤措弰鞛愲毳� 氤搓碃頄堨姷雼堧嫟. 觳Ц, 須岇偓電� 氙戈淡 鞝滌“鞐呾泊鞕� 韽磩鞝侅澑 鞎诫 氍检 臧滊皽 靹滊箘鞀� 瓿勳暯鞚� 觳搓舶頃橃棳 頄ロ泟 鞛勳儊 氍检 靸濎偘鞚� 頇曤炒頄堨姷雼堧嫟. 霊橃Ц, 歆勴枆 欷戩澑 1b靸� 鞖╇焿 歃濍焿 鞐瓣惮(NCT 06014086)鞐愳劀 雱� 氩堨Ц 旖旐樃韸胳潣 雼れ劘 氇� 頇橃瀽 欷� 雱� 氇呾棎 雽�頃� 氤戨Μ 瓴瓣臣臧� 鞚挫牅 鞝滉车 臧�電�頃橂嫟瓿� 氚濏様鞀惦媹雼�. 鞎堨爠靹�, 須姤 霕愲姅 鞛 甏�霠� 鞝曤焿鞝� 臁瓣贝鞚� 鞝滉车霅橃 鞎婌晿鞙茧┌, 韴瀽鞛愲摛鞚� 鞝勳泊 靹鸽秬靷暛鞚� 鞙勴暣 攵�搿� 99.1 氚� 99.2毳� 彀胳“頃挫暭 頃╇媹雼�.
Phio Pharmaceuticals (PHIO) a d茅pos茅 un formulaire 8-K dat茅 du 25 juillet 2025 pour annoncer deux communiqu茅s de presse. Premi猫rement, la soci茅t茅 a conclu un accord complet de services de d茅veloppement de substances m茅dicamenteuses avec un fabricant am茅ricain, garantissant la production de mat茅riel clinique futur. Deuxi猫mement, elle a r茅v茅l茅 que les r茅sultats pathologiques sont d茅sormais disponibles pour quatre des cinq patients de la quatri猫me cohorte de son 茅tude de phase 1b en cours avec escalade de dose (NCT 06014086) 茅valuant l鈥橧NTASYL PH-762 en n茅oadjuvant. Aucun d茅tail quantitatif sur la s茅curit茅, l鈥檈fficacit茅 ou les aspects financiers n鈥檃 茅t茅 fourni ; les investisseurs doivent consulter les annexes 99.1 et 99.2 pour plus d鈥檌nformations.
Phio Pharmaceuticals (PHIO) reichte am 25. Juli 2025 ein Formular 8-K ein, um zwei Pressemitteilungen zu melden. Erstens schloss das Unternehmen eine umfassende Vereinbarung 眉ber die Entwicklung von Arzneistoffen mit einem US-amerikanischen Hersteller ab und sicherte so die Produktion von zuk眉nftigen klinischen Materialien. Zweitens gab es bekannt, dass Pathologieergebnisse nun f眉r vier von f眉nf Patienten in der vierten Kohorte seiner laufenden Phase-1b-Dosissteigerungsstudie (NCT 06014086) zur Bewertung des neoadjuvanten INTASYL PH-762 vorliegen. Quantitative Angaben zu Sicherheit, Wirksamkeit oder finanziellen Bedingungen wurden nicht gemacht; Investoren sollten die Anh盲nge 99.1 und 99.2 f眉r vollst盲ndige Details konsultieren.
FAQ
What did Phio Pharmaceuticals disclose in its 25 July 2025 Form 8-K?
Which clinical study is referenced in the 8-K for PHIO?
Did the filing include safety or efficacy data for PH-762?
What type of agreement did PHIO enter into?
Are financial terms of the manufacturing agreement disclosed?
